Remedium Capital Partners, LLC
Remedium Capital Partners, LLC reported 6 US-listed holdings worth $451.6 million in its 13F for the quarter ended 30 June 2026, filed 7 August 2026. Its largest: Oruka Therapeutics Inc. (33.0%), Spyre Therapeutics Inc. (28.8%) and Apogee Therapeutics Inc. (17.2%). Against the quarter before, it opened 1 position, added to 2, trimmed 0 and sold out of 1.
The 6 largest of its 6 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.
What the fund reported holding at each quarter's end; hover a bar for the number of positions
What its reported holdings returned
Held through each quarter, the holdings it reported returned +118.4% over the 2 quarters to 30 June 2026, against +9.5% for the S&P 500.
Not the fund's own return: each 13F's holdings are kept unchanged until the next one, so trades inside a quarter, dividends, cash and fees are left out. A rough guide to how its picks have done over time.
What it did on the quarter
Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held
Opened 1
- Crescent Biopharma Inc. CBIO$6.5 million
Added to 2
- Spyre Therapeutics Inc. SYRE+7,938 shares · +1%
- Apogee Therapeutics Inc. APGE+3,100 shares · +1%
Sold out of 1
- Crescent Biopharma Inc.$6.6 million last quarter
What it holds
| Company | Shares | Value | Of its book | Change in shares |
|---|---|---|---|---|
| Oruka Therapeutics Inc. ORKA | 1.6M | $149.0 million | 32.99% | no change |
| Spyre Therapeutics Inc. SYRE | 1.5M | $130.0 million | 28.78% | +7.9K |
| Apogee Therapeutics Inc. APGE | 586.7K | $77.9 million | 17.24% | +3.1K |
| Galecto Inc. DMRA | 2.0M | $53.2 million | 11.78% | no change |
| Jade Biosciences Inc. JBIO | 1.6M | $35.1 million | 7.76% | no change |
| Crescent Biopharma Inc. CBIO | 361.2K | $6.5 million | 1.44% | new |